Developmental pharmacokinetic changes of Lamivudine in infants and children
about
The role of formulation on the pharmacokinetics of antiretroviral drugs.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.Antiretroviral therapy during the neonatal period.
P2860
Developmental pharmacokinetic changes of Lamivudine in infants and children
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Developmental pharmacokinetic changes of Lamivudine in infants and children
@ast
Developmental pharmacokinetic changes of Lamivudine in infants and children
@en
type
label
Developmental pharmacokinetic changes of Lamivudine in infants and children
@ast
Developmental pharmacokinetic changes of Lamivudine in infants and children
@en
prefLabel
Developmental pharmacokinetic changes of Lamivudine in infants and children
@ast
Developmental pharmacokinetic changes of Lamivudine in infants and children
@en
P2093
P2860
P356
P1476
Developmental pharmacokinetic changes of Lamivudine in infants and children
@en
P2093
Adriana H Tremoulet
Edmund V Capparelli
Kulkanya Chokephaibulkit
Mark Mirochnick
Mina Nikanjam
Ross McKinney
Tim R Cressey
P2860
P304
P356
10.1177/0091270011426563
P577
2011-12-16T00:00:00Z